Defective platelet β-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders

References

• Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 1990; 4: 157–178
   PubMed Web of Science ®Google Scholar
• Baker RI, Manoharan A. Platelet function in myeloproliferative disorders and sequential studies show multiple platelet abnormalities and change with time. Eur J Haematol 1988; 40: 267–272
   PubMed Web of Science ®Google Scholar
• Bennett JS. Acquired platelet function defects. Platelets in thrombotic and non thrombotic disorders, P Gresele, CP Page, V Fuster, J Vermylen. Cambridge University Press, Cambridge 2002; 689–706
   Google Scholar
• Barbui T, Finazzi G. Thrombocytosis and thrombocythemia. Platelets in thrombotic and non thrombotic disorders, P Gresele, CP Page, V Fuster, J Vermylen. Cambridge University Press, Cambridge 2002; 623–638
   Google Scholar
• Viero P, Cortelazzo S, Bassan R, Barbui T. Effects of aspirin on platelet 5-hydroxytryptamine and β-thromboglobulin plasma levels in patients with myeloproliferative disorders. Thromb Haemost 1982; 48: 125–129
   PubMed Web of Science ®Google Scholar
• Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271–278
   PubMed Web of Science ®Google Scholar
• Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110: 116–124
   PubMed Web of Science ®Google Scholar
• Kaywin P, McDonough M, Insel PA, Shattil SJ. Platelet function in essential thrombocythemia: Decrease epinephrine responsiveness associated to α-adrenergic receptor. New Engl J Med 1978; 299: 505–509
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia: Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487–2496
   PubMed Web of Science ®Google Scholar
• Zahavi J, Zahavi M, Firsteter E, Frish B, Turleanu R, Rachmani R. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991; 47: 326–332
   PubMed Web of Science ®Google Scholar
• Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979; 54: 1258–1271
   PubMed Web of Science ®Google Scholar
• Parise P, Huybrechts E, Grasselli S, Falcinelli F, Nenci GG, Gresele P, Vermylen J. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders. Acta Haematol 1991; 85: 88–92
   PubMedGoogle Scholar
• Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 1995; 49: 289–293
   PubMed Web of Science ®Google Scholar
• Meschengieser S, Blanco A, Woods A, Maugeri N, Fernandez J, Dupont J, Lazzari MA. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders. Thromb Res 1987; 48: 311–319
   PubMedGoogle Scholar
• Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemost 1982; 48: 41–45
   PubMed Web of Science ®Google Scholar
• Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993; 70: 736–742
   PubMed Web of Science ®Google Scholar
• Pareti FI, Capitanio A, Mannucci L, Ponticelli C, Mannucci PM. Acquired dysfunction due to the circulation of ‘exhausted’ platelets. Am J Med 1980; 69: 235–240
   PubMed Web of Science ®Google Scholar
• Nenci GG, Gresele P, Agnelli G, Parise P. Intrinsically defective or exhausted platelets in hairy cell leukemia?. Thromb Haemost 1981; 46: 572
   PubMedGoogle Scholar
• Mehta P, Mehta J, Ross M, Ostrowski N, Player D. Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera. Arch Intern Med 1985; 145: 1225–1227
   PubMedGoogle Scholar
• Mazzuccato M, De Marco L, De Angelis V, De Roia D, Bizzarro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: Decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989; 73: 369–374
   PubMedGoogle Scholar
• Okuma M, Takayama H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol 1982; 51: 469–477
   PubMedGoogle Scholar
• Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95: 82–86
   PubMed Web of Science ®Google Scholar
• Kaplan R, Gabbeta J, Sun L, Mao GF, Rao AK. Combined defect in membrane expression and activation of platelet GPIIb/IIIa complex without primary sequence abnormalities in myeloproliferative disease. Br J Haematol 2000; 111: 954–964
   PubMed Web of Science ®Google Scholar
• Holmsen H. Platelet secretion and energy metabolism. Haemostasis and thrombosis. Basic principles and clinical practice, RW Colman, J Hirsh, VJ Marder, EW Salzman. JB Lippincott, Philadelphia, PA 1994; 524–545
   Google Scholar
• Emiliani C, Martino S, Orlacchio A, Vezza R, Nenci GG, Gresele P. Platelet glycohydrolase activities: Characterization and release. Cell Biochem Funct 1995; 13: 31–39
   PubMed Web of Science ®Google Scholar
• Ciferri S, Emiliani E, Guglielmini G, Orlacchio A, Nenci GG, Gresele P. Platelets release their lysosomal content in vivo in humans upon activation. Thromb Haemost 2000; 83: 157–164
   PubMed Web of Science ®Google Scholar
• World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, ES Jaffe, NL Harris, H Stein, JW Vardiman. IARC Press, Lyon 2001; 291–321
   Google Scholar
• Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, Nenci GG, Davi G. Platelet activation markers in patients with peripheral arterial disease – A prospective comparison of different platelet function tests. Thromb Haemost 1997; 78: 1434–1437
   PubMed Web of Science ®Google Scholar
• Vezza R, Roberti R, Nenci GG, Gresele P. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704–2713
   PubMedGoogle Scholar
• Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davi G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41: 1013–1020
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 7: 248–254
   Web of Science ®Google Scholar
• Emiliani C, Beccari T, Stirling JL, Sciarra R, Orlacchio A. New biospecific chromatographies for β-hexosaminidase. Macromolecular biorecognition, I Chaiken, E Chicone, A Fontana, P Neri. The Humana Press, Clifton, NJ 1988; 309–319
   Google Scholar
• Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activationin vivo. Blood 1981; 57: 199–202
   PubMed Web of Science ®Google Scholar
• Handa M, Watanabe K, Kawai Y, Kamata T, Koyama T, Nagai H, Ikeda Y. Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia–IIa (α2 β1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemostas 1995; 73: 521–528
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J. Impaired platelet binding of fibrinogen due to a lower number of GPIIb/IIIa receptors in polycythemia vera. Thromb Res 1998; 91: 287–295
   PubMedGoogle Scholar
• Rossi R, Giannini S, Mencarelli S, Falcinelli E, Orlacchio A, Emiliani C, Gresele P. Lysosomal β-N-acetylhexosoaminidase is a primer of platelet activation. Pathophysiol Haemost Thromb 2004; 6, (Abstract)
   Google Scholar
• Martino S, Emiliani C, Tabilio A, Falzetti F, Stirling JL, Orlacchio A. Distribution of α- and β-subunits of β-N-acetylhexosaminidase as a function of leukaemic cell types. Biochim Biophys Acta 1997; 1335: 5–15
   PubMedGoogle Scholar
• Emiliani C, Beccari T, Tabilio A, Orlacchio A, Hossein R, Stirling JL. An enzyme with properties similar to those of β-N-acetylhexosaminidase S is expressed in the promyelocytic cell line HL-60. Biochem J 1990; 267: 111–117
   PubMedGoogle Scholar
• Drexler HG, Gaedicke G, Novotny J, Minowada J. Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells II. Hexosaminidase I isoenzyme. Cancer Res 1986; 58: 245–251
   Google Scholar
• Hepbildikler S, Sandhoff R, Kölzer M, Proia RL, Sandhoff K. Physiological substrates for human lysosomal β-hexosaminidase S. J Biol Chem 2002; 25: 2562–2572
   Google Scholar
• Kytzia HJ, Sandhoff K. Evidence for two different active sites on human β-hexosaminidase. A Interaction of GM2 activator protein with β-hexosaminidase A. J Biol Chem 1985; 260: 7568–7572
   PubMedGoogle Scholar
• Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, Suzuki K. The metabolic and molecular bases of inherited disease. Vol. III, 8th. McGraw-Hill, New York 2001; 3827–3876
   Google Scholar